Search Results

You are looking at 1 - 10 of 990 items for :

  • "controlled trial" x
Clear All
Interventional Medicine and Applied Science
Authors: Sirous Azizi, Afsaneh Dadarkhah, Zahra Rezasoltani, Seyed Ahmad Raeissadat, Reza Kazempoor Mofrad and Sharif Najafi

hypothesis was that aquatic exercise would be associated with changes in symptoms, gait, and balance parameters. Materials and Methods Design and setting The study was a single-blind randomized controlled trial. The

Open access
Interventional Medicine and Applied Science
Authors: Sirous Azizi, Afsaneh Dadarkhah, Zahra Rezasoltani, Seyed Ahmad Raeissadat, Reza Kazempoor Mofrad and Sharif Najafi

controlled trial. The trial was conducted from September 2016 through May 2017 in an outpatient clinic of the Department of Physical Medicine and Rehabilitation of a University of Medical Sciences. Recruitment We recruited

Open access
Journal of Behavioral Addictions
Authors: William Van Gordon, Edo Shonin, Thomas J. Dunn, Javier Garcia-Campayo, Marcelo M. P. Demarzo and Mark D. Griffiths

use of MAT in the aforementioned workaholism clinical case study (and also during studies of MAT involving other forms of behavioral addiction), the purpose of this study was to conduct a controlled trial to investigate whether the salutary effects of

Open access

, online interventions that can effectively reduce PPU. Therefore, the aim of the present study is to test the effectiveness of a web-based self-help program (Hands-off) to reduce PPU in a two-armed randomized controlled trial (RCT), while also considering

Open access
Journal of Behavioral Addictions
Authors: Nancy J. Keuthen, Barbara O. Rothbaum, Jeanne Fama, Erin Altenburger, Martha J. Falkenstein, Susan E. Sprich, Megan Kearns, Suzanne Meunier, Michael A. Jenike and Stacy S. Welch

Abstract

Background and aims

Limited treatment options are available for trichotillomania (TTM) and most have modest outcomes. Suboptimal treatment results may be due to the failure of existing approaches to address all TTM styles.

Methods

Thirty-eight DSM-IV TTM participants were randomly assigned across two study sites to Dialectical Behavior Therapy (DBT) -enhanced cognitive-behavioral treatment (consisting of an 11-week acute treatment and 3-month maintenance treatment) or a minimal attention control (MAC) condition. MAC participants had active treatment after the 11-week control condition. Follow-up study assessments were conducted three and six months after the maintenance period.

Results

Open trial treatment resulted in significant improvement in TTM severity, emotion regulation (ER) capacity, experiential avoidance, anxiety and depression with changes generally maintained over time. In the randomized controlled trial, those with active treatment had greater improvement than those in the MAC condition for both TTM severity and ER capacity. Correlations between changes in TTM severity and ER capacity were not reported at post-treatment but did occur in maintenance and follow-up indicating reduced TTM severity with improved ER capacity.

Conclusions

DBT-enhanced cognitive-behavioral treatment is a promising treatment for TTM. Future studies should compare this approach to other credible treatment interventions and investigate the efficacy of this approach in more naturalistic samples with greater comorbidity.

Open access

The prospective controlled study was designed for comparing the influence of methimazole (MMI + placebo)(control group) and MMI + pentoxiphylline (PTX) with respect to grades of Thyroid Associated Ophthalmopathy (TAO). The control group consisted of 112 patients with hyperthyroidism (mean age 44.0 ± 12.4 yr, 83 females and 29 males). PTX treated group of 112 (mean age 47.7 ± 10.2 yr, 83 female and 29 male) hyperthyroid patients were treated with MMI + PTX. At the onset of the study there were no remarkable differences between the two treated groups. After six- and twelve-month observation periods the manifestations of TAO with moderate and severe forms were significantly lower in the PTX treated patients. Various risk factors were analyzed in both groups. Smoking by itself without genetic factors greatly increased the risk of TAO (OR: 7.1, CI 95% 9.3–5.4). If the smoking habit was associated with a genetic background, the manifestation of TAO significantly increased (OR: 9.2 CI 95%, 12.1–6.9, p < 0.0001). PTX therapy had a beneficial preventive effect on the manifestation of eye symptoms and decreased the number of smoking patients both with and without genetic susceptibility (OR: 2.62 CI 95%, 1.5–3.7, p < 0.001 and 2.12: 95% CI 1.5–3.1, p < 0.001), respectively. It was concluded that PTX was able to decrease the development of TAO during a 1-year observation period, therefore, the administration of this drug was advised if the patients refused to abstain from smoking.

Restricted access

2003 A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's Disease Ann Neurol 54 406 14 . 8

Restricted access

Aim and objective: To determine the efficacy and safety profile of corticosteroid on the clinical course of prolonged intrahepatic cholestasis due to acute hepatitis A. Method: We prospectively studied patients of acute hepatitis A with prolonged cholestasis (more than 12 weeks with debilitating symptoms in the form of anorexia, weight loss and pruritis disturbing night sleep) over a period of five years. The patients were randomly assigned to two groups of ursodeoxycholic acid and prednisolone (Group A) and ursodeoxycholic acid and placebo (Group B). They were assessed for cumulative mean decrease in bilirubin at day 3, 7 and then weekly till normalization of bilirubin. Quality of life was assessed in both groups on the basis of pruritis, anorexia, performance status improvement and work hour loss in days. Results: Out of 84 patients of acute hepatitis A, 21 patients had prolonged cholestatic hepatitis. Eleven patients (group A) were given ursodeoxycholic acid and prednisolone. Ten patients (group B) were given ursodeoxycholic acid and placebo. In group A, male: female ratio was 7:4, with a mean age of 21 years (range 13–30 years). The mean bilirubin was 29.4 mg/dl (range 24.9–34.6 mg/dl), aspartate aminotransferase (AST) 104 (range 84–124 U/L), alanine (ALT) aminotransferase 74 U/L (range 51–98 U/L), alkaline phosphatase (AP) 643 (range 460–870 U/L), prothrombin time (PT) prolongation in seconds 3.09 (range 4–7) and protein/albumin 7.1/4.2 (range 7.6–6.4/3.6–4.7 gm/dl). The decrease in bilirubin in group A (cumulative mean) at day 3, 7, 14, 21, 28, 35, 42, 49 was 20.1%, 45.6%, 58.6%, 64.6%, 71.7%, 76.1%, 80.5% and 86.4%, respectively. The mean time for bilirubin normalization was 44 days (range 28–84 days). In group B, male: female ratio 5:5, with a mean age of 21.5 years (range 11–35 years). The mean bilirulin, AST, ALT, AP, PT prolongation (in seconds) protein-albumin were 28.6 (range 11–35 mg/dl), 81 (range 43–112 U/L), 64 U/L (range 39–91 U/L), 702 (range 326–890 U/L), 3.6 (range 2–7) and 6.57/3.7 (range 7.6–5.8/3.2–4.2 gm/dl), respectively. The decrease in bilirubin at day 3, 7, 4, 21, 28, 35, 42, 49 was 2.1%, 5.9%, 11.9%, 19.1%, 25.1%, 29.3%, 33.3% and 38.5%, respectively. The mean time for bilirubin normalization was 94 days (range 74–138 days). p < 0.05 at day 3, 7, 14, 21, 28, 35, 42 and 49 days. Pruritis responded within a mean of 5 days (range 4–8 days) and 24 days (range 18–45 days) in group A and group B, respectively. Anorexia, performance status improvement occurred early in group A and work hour loss was more in group B. None of the patients developed side-effects to corticosteroid. Conclusion: Both groups of prolonged choleastatic hepatitis A were of comparable severity in term of maximal serum bilirubin and transaminases. Prednisolone resulted in symptomatic relief and a rapid initial drop in serum bilirubin levels followed by a persistent fall. No adverse event was recorded. So, prednisolone can be used in debilitating symptoms due to cholestasis in acute viral hepatitis A.

Restricted access

gastroplication for the treatment of gastro-oesophageal reflux disease: a randomised, sham-controlled trial Gut 56 20 8 . 4

Restricted access

Freedman, B.: Placebo-Controlled Trials and the Logic of Clinical Purpose. IRB: A Review of Human Subjects Research, 1990, 12 , 1–6. Freedman B

Restricted access